Trial Profile
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Acronyms RESTORE S
- Sponsors PDL BioPharma
- 09 Oct 2020 This trial is completed in Ireland, according to European Clinical Trials Database record.
- 30 Sep 2009 New trial record.